KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Jia Yu, Anwen Xiong, Qiming Wang, Jianhua Chen, Hongrui Niu, Chengzhi Zhou, Panwen Tian, Wu Zhuang, Jie Li, Jing Wang, Junguo Lu, Kangsheng Gu, Jinsheng Shi, Jun Guo, Yonghui Di, Dongqing Lv, Debin Sun, Liming Cao, Zhixiong Yang, Jingxun Wu, Liyun Miao, Yueyin Pan, Chong Li, Xiaohong Wu, Jie Yin, Xiang Wang, Meili Sun, Miao He, Shundong Cang, Haohui Fang, Ping Chen, Min Zhang, Xinmei Yang, Hui Zhao, Jian Feng, Xuezhen Ma, Sheng Hu, Jian Lu, Xin Zhao, Zhixiang Zhuang, Yilan Sun, Xu Sun, Bing Yu, Chaonan Zhu, Jianghua Chen, June Xu, Kai Wang, Caicun Zhou

Signal Transduct Target Ther 11(1) 324

PMID42586967
PMCIDPMC13470399
DOI10.1038/s41392-026-02904-0
发表日期2026-08-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations. In this phase III, randomized, double-blind trial in China, 336 eligible patients with advanced nonsquamous NSCLC harboring EGFR L858R or exon 19 deletion (ex19del) were assigned (2:1) to receive either mefatinib (60 mg daily, n = 223) or gefitinib (250 mg daily, n = 113). The primary endpoint was progression-free survival (PFS), assessed by an independent review committee (IRC). The trial is registered with chinadrugtrials.org.cn (CTR20192297). After a median follow-up of 15.9 months for mefatinib and 18.5 months for gefitinib, mefatinib demonstrated a significantly longer median IRC-assessed PFS compared to gefitinib (13.7 vs. 9.7 months; hazard ratio [HR] = 0.68; 95% confidence intervals [CI]: 0.53-0.87; p = 0.002). The 30-month overall survival rate was 60.2% for mefatinib and 54.3% for gefitinib. Patients with EGFR ex19del had comparable PFS for both treatment arms (p > 0.100), whereas patients with EGFR L858R had significantly longer median PFS when treated with mefatinib than gefitinib (13.7 vs 8.3 months HR = 0.55 [95% CI: 0.38-0.78]; p = 0.001). Patients with EGFR L858R had a 30-month overall survival rate of 56.6% with mefatinib and 43.7% with gefitinib. Treatment-related adverse events ≥grade 3 were reported in 45.7% of the mefatinib group and 24.8% of the gefitinib group. No new safety signals were observed for mefatinib. Mefatinib demonstrated superior efficacy to gefitinib with a similar tolerability profile in the first-line treatment of EGFR-mutated advanced NSCLC.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Progression-free survival of the cohort. a Kaplan‒Meier curve comparing progression-free survival based on the independent review committee of the mefatinib and gefitinib groups of the full analysis cohort. The risk table below shows the number of cases included and censored per time point. b Forest plot showing the subgroup analysis of the impact of various clinical factors on progression-free survival

A

progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 3

Progression-free survival based on EGFR genotype. Kaplan‒Meier curves comparing progression-free survival based on the independent review committee between patients with EGFR exon 19 deletion (ex19del) ( a ) and patients with EGFR L858R ( b ) treated with mefatinib and gefitinib. The risk table below shows the number of cases included and censored per time point

A

progression-free survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

progression-free survival

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study participant flow diagram
非 KM Figure